Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H15N2O4PS |
| Molecular Weight | 302.287 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CC1=C(N=C(N)S1)C2=CC=C(O2)P(O)(O)=O
InChI
InChIKey=XJMYIJPPDSZOPN-UHFFFAOYSA-N
InChI=1S/C11H15N2O4PS/c1-6(2)5-8-10(13-11(12)19-8)7-3-4-9(17-7)18(14,15)16/h3-4,6H,5H2,1-2H3,(H2,12,13)(H2,14,15,16)
| Molecular Formula | C11H15N2O4PS |
| Molecular Weight | 302.287 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Managlinat dialanetil (MB06322 or CS-917) is an inhibitor of fructose 1,6-bisphphosphatase.
Managlinat dialanetil is a bisamidate prodrug and its activation requires a two-step enzyme catalyzed reaction. Metabasis Therapeutics Inc in collaboration with Daiichi Sankyo Co Ltd was developing managlinat dialanetil for the potential treatment of type 2 diabetes.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. | 2006 Jun |
|
| Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes. | 2007 Oct |
|
| CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats. | 2008 Dec 28 |
|
| Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. | 2009 Nov 25 |
|
| Fructose-1,6-bisphosphatase regulates glucose-stimulated insulin secretion of mouse pancreatic beta-cells. | 2010 Oct |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:33:25 GMT 2023
by
admin
on
Sat Dec 16 18:33:25 GMT 2023
|
| Record UNII |
9379MH4CAL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11289630
Created by
admin on Sat Dec 16 18:33:26 GMT 2023 , Edited by admin on Sat Dec 16 18:33:26 GMT 2023
|
PRIMARY | |||
|
9379MH4CAL
Created by
admin on Sat Dec 16 18:33:26 GMT 2023 , Edited by admin on Sat Dec 16 18:33:26 GMT 2023
|
PRIMARY | |||
|
261365-11-1
Created by
admin on Sat Dec 16 18:33:26 GMT 2023 , Edited by admin on Sat Dec 16 18:33:26 GMT 2023
|
PRIMARY | |||
|
MB-05032
Created by
admin on Sat Dec 16 18:33:26 GMT 2023 , Edited by admin on Sat Dec 16 18:33:26 GMT 2023
|
PRIMARY | Description: IC50 Value: 16 nM (Human Liver FBPase) (1) MB05032 is a special and efficacious GNG inhibitor targeted the AMP binding site of fructose 1,6-bisphosphatase (FBPase) with an IC50 value of 16 nM. Oral delivery of MB05032 was achieved by using the bisamidate prodrug MB06322 (CS-917), which is converted to MB05032 in two steps through the action of an esterase and a phosphoramidase. in vitro: MB05032 inhibits human liver FBPase with a potency (IC50 = 16 +/- 1.5 nM) significantly greater than the natural inhibitor, AMP (IC50 = 1 .MU.M), and the most well characterized AMP mimetic, ZMP (IC50 = 12 +/- 1.4 .MU.M). MB05032 inhibits rat FBPase 3-fold weaker (IC50 of 61 +/- 4 nM) than human FBPase, whereas AMP is 20-fold weaker as an inhibitor. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Amino acid, Anti-hyperglycaemic, Organo-phosphorus compound and Small molecule; Mechanism of Action: Fructose bisphosphatase inhibitor and Gluconeogenesis inhibitor; Highest Development Phase: Discontinued Type 2 diabetes mellitus; Most Recent Events: 29 Jun 2007 Data presented at the 67th Scientific Sessions of the American Diabetes Association (ADA-2007), added to the Diabetes pharmacodynamics section, 26 Jun 2007 Daiichi Sankyo completes a phase IIb trial in Diabetes in the US
|
